Adamas Pharma patents expiration
1. Gocovri patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895615 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895616 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8796337 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895617 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895618 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895614 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8889740 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8389578 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Jan, 2028
(4 years from now) | |
| US11197835 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9867793 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US8741343 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9867792 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9867791 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US9877933 | ADAMAS PHARMA | Method of administering amantadine prior to a sleep period |
Dec, 2030
(7 years from now) | |
| US10646456 | ADAMAS PHARMA | Methods of administering amantadine |
Jun, 2034
(10 years from now) | |
| US10154971 | ADAMAS PHARMA | Methods of administering amantadine |
Dec, 2034
(11 years from now) | |
| US11065213 | ADAMAS PHARMA | Amantadine compositions and preparations thereof |
Aug, 2038
(14 years from now) | |
| US11077073 | ADAMAS PHARMA | Methods of using amantadine compositions |
Aug, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia in patients with parkinson'...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
GOCOVRI family patents
2. Osmolex Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895616 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895615 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8796337 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895617 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US9072697 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8889740 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8987333 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895614 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895618 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8574626 | ADAMAS PHARMA | Osmotic device containing amantadine and an osmotic salt |
Nov, 2025
(2 years from now) | |
| US8389578 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Jan, 2028
(4 years from now) | |
| US8252331 | ADAMAS PHARMA | Osmotic device containing amantadine and an osmotic salt |
Mar, 2030
(6 years from now) | |
| US10213393 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10500170 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10500171 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10512617 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10500172 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10213394 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of parkinson's disease; Treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; Treatment of drug-induced extrapyramidal reaction in adult patients; A ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
OSMOLEX ER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic